Abstract N 6-methyladenosine (m 6 A) is a well-known post-transcriptional modification that
is the most common type of methylation in eukaryotic mRNAs. The regulation of m 6 A is …

Evidence of human acute myeloid leukemia stem cells (AML LSCs) was first reported nearly
2 decades ago through the identification of rare subpopulations of engrafting cells in …

Fat mass and obesity-associated protein (FTO), an RNA N 6-methyladenosine (m 6 A)
demethylase, plays oncogenic roles in various cancers, presenting an opportunity for the …

Summary R-2-hydroxyglutarate (R-2HG), produced at high levels by mutant isocitrate
dehydrogenase 1/2 (IDH1/2) enzymes, was reported as an oncometabolite. We show here …

All cancers emerge after a period of clonal selection and subsequent clonal expansion.
Although the evolutionary principles imparted by genetic intratumour heterogeneity are …

The advent of iPSCs has brought about a significant transformation in stem cell research,
opening up promising avenues for advancing cancer treatment. The formation of cancer is a …

Somatic mutations in DNMT3A are recurrent events across a range of blood cancers.
Dnmt3a loss of function in hematopoietic stem cells (HSCs) skews divisions toward self …

Cancer is the leading disease-related cause of death in children in developed countries.
Arising in the context of actively growing tissues, childhood cancers are fundamentally …

Abstract Additional Sex Combs-Like 1 (ASXL1) is mutated at a high frequency in all forms of
myeloid malignancies associated with poor prognosis. We generated a Vav1 promoter …

There is experimental and observational evidence that the cells of the leukemic clone in
acute myeloid leukemia (AML) have different phenotypes even though they share the same …